

INSTITUTIONAL BIOSAFETY COMMITTEE MINUTES
 Recombinant DNA(RM)
 Meeting #274
 Tuesday, March 10, 2026
Hybrid - In Person Location FCT3 1 and 8 - 1:00 PM

Members Present

Xue Hao, Assistant Professor
 Bisrat Godefay Debeb, Associate Professor
 Kwong K Wong, Professor
 Izabela Fokt, Assistant Professor
 Marcos Roberto Estecio, Professor
 Xiang-Yang Han, Professor
 Dina H Ray, Research Nurse Manager
 Zahid H Siddik, Professor
 Pijus K Mandal, Institute Research Scientist
 Chavaun H LeBlanc, Mgr, Environ Health & Safety
 Hai T Tran, Associate Professor
 Hesham Amin, Professor
 Guang Peng, Professor
 Rajneesh Pathania, Assistant Professor
 Linette M Leadon, Dir, EHS Sustain & Emerg Mgmt
 Krithika Srinivasan, Assistant Professor
 Jody Swain, Associate Professor
 Vidya Gopalakrishnan, Associate Professor
 Pramod N Nehete, Professor

Members Absent

Tora D Ogunmakin, Assoc Dir, Ambulatory Nursing
 Shilpa S. Dhar, Assistant Professor
 Erica J Moore, Assistant Professor
 Niki M. Zacharias Millward, Associate Professor
 Guocan Wang, Associate Professor
 Yang Lu, Supv, Laboratory & Research
 Humam N Kadara, Professor
 Taiping Chen, Professor

Community Members Present

Others Present

Robert Plant, Safety Specialist
 Allyson Wakefield, Program Manager
 Madeline McAllister, Compliance Analyst
 Cheryl Smith, Safety Specialist
 Tekchheng Tam, Safety Specialist
 Joseph E Jacobs, Safety Specialist
 Brittany N Kleb, Assoc Dir, Institutional Compl
 Edith Plants Paris, Compliance Analyst
 David A Imperial, Safety Specialist
 Marivonne Rodriguez, Principal Safety Specialist
 Dana Blackburn, Compliance Analyst
 Nastassia Harper, Safety Specialist

Others Absent

1. APPROVAL OF THE PAST MEETING MINUTES

Meeting	Votes-Yes	Votes-No	Votes-Abstain	Votes-Recuse
IBC Recombinant meeting on Tuesday, February 10, 2026	18	0	2	0

2. CONFLICT OF INTEREST RECUSAL

Attendee	Project	Comment
Vidya Gopalakrishnan	RM00001641-RN02	Dr. Gopalakrishnan is the PI of this registration.
Vidya Gopalakrishnan	RM00008708-RN00	Dr. Gopalakrishnan is the PI of this registration.
Guocan Wang	TA00002415-RN01_AM2	Dr. Wang is the PI of this non-administrative modification.
Guocan Wang	RM00002407-RN01_AM20	Dr. Wang is the PI of this non-administrative modification.
Vidya Gopalakrishnan	TA00008733-RN00	Dr. Gopalakrishnan is the PI of this registration.
Humam N Kadara	RM00003782-RN01_AM9	Dr. Kadara is the PI of this non-administrative modification.
Humam N Kadara	RM00008505-RN00_AM1	Dr. Kadara is the PI of this non-administrative modification.
Vidya Gopalakrishnan	RM00001784-RN02	Dr. Gopalakrishnan is the PI of this registration.
Guang Peng	RM00000645-RN02_AM2	Dr. Peng is the PI of this non-administrative modification.

3. REPORT OF THE ADVERSE EVENTS

Krithika Srinivasan, M.D.; Assistant Professor, Infections Diseases - Nothing to report.

4. REPORT OF THE SAFETY COMMITTEE

Linette Leadon, M.S.; Dir, Fac Mgt EHS Administration - Nothing to report.

5. REPORT OF RECOMBINANT DNA (RM) SUBCOMMITTEE

Marcos Roberto Estecio, Ph.D.; Professor, Epigenet & Mol Carcinogenesis

6. NEW PROTOCOLS

BSL 1: NEW PROTOCOLS

There are no new protocols to review for this meeting.

NEW TRANSGENIC ANIMAL PROTOCOLS:

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0
Investigator :			Andrea Viale	
Document No. :			TA00008647-RN00	
NIH Guidelines Category :			III-F-8.	

NEW TRANSGENIC ANIMAL PROTOCOLS:

Agents :

Species	ACUF#	Genes Inserted	Genes Deleted
Mouse	00001843-RN02	B6.129S2-A1btm1(cre/ERT2)Mtz/J, FVB.129-Gt(ROSA)26Sortm1(MYC)Djmy/J, B6.129P2-Lgr5tm1(cre/ERT2)Cle/J, C57BL/6-Apctm1Tyj/J, B6.Cg-Tg(Vil1-cre/ERT2)23Syr/J, FSF-KrasG12D, K19CreER, p48-Cre, Rosa LSL-rtTA-IRES-GFP, Rosa26-CreER, TetO-Kras, ProCPA1CreERT2, Rosa RTTA / Rosa-LSLrtTA, LSL-KRAS, LUCfl, YFPfl, LSL-YFP, LSL-TP53R172H, GliLacZ, GT(ROSA)26Sor-TM4(ACTB-tdTomato,-EGFP)Luo/J, aSMA, ER-Tert, TetO-Braf, TetoNrasQ61K, iDTR, pdx1Cre, PDX1 GFP, Mist1-Cre, Sox9-Cre, nTnG, R26R-Brainbow2.1, Cclal1-cre/ERT, Dclk1-DTR-zsGreen, krt8-Cre, aSMA-TK, H2B-mCherry, OVGPI1-Cre, B6.Cg-Tg(Tyr-cre/ERT2)13BosBrafm1Mmcm Ptentm1Hwu/BosJ, C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ, Tg(Krt8-cre/ERT2)17Bln/J, C57BL/6-Tg(CAG-tdTomato,Actb/EGFP)1Erv/J, B6J.129(B6N)-Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/J, B6J.129(Cg)-Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh/J, Krt19tm1(cre/ERT)Ggu/J, BRafCA, Tyr::CreERT2	C57BL/6-Apc tm1Tyj/J, p53 Lox, EGR1-null, IL6-null, PtenloxP, smad4fl, ink4/arfl, mTR, Snf5 L/L, Ezh2fl, Brg1fl, B6.129-Hif1a tm3Rsjo/J

Biosafety Level : BSL1
Meeting Notes : This transgenic protocol seeks to develop mouse models to study how after resolution of injury there can be long lasting inflammation or inflammation memory that predispose to tumorigenesis. IACUC is current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	19	0	1	0
Investigator :			Vidya Gopalakrishnan	
Document No. :			TA00008733-RN00	
NIH Guidelines Category :			III-F-8.	
Agents :				
Species	ACUF#	Genes Inserted	Genes Deleted	
Mouse	00002718-RN00		VHL	
Biosafety Level :			BSL1	
Meeting Notes :			This is a transgenic animal protocol to study VHL tumor suppressor in Medulloblastoma. VHL2-lox knock out mice will be purchase from the Jackson Laboratory. IACUC protocol is current.	

BSL 2: NEW PROTOCOLS

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Nitin Jain	
Document No. :			RM00008595-RN00	
NIH Guidelines Category :			III-C-1.	
Agents :				
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
retrovirus		No		Murine gamma retrovirus
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
Autologous Primary Human T Cells			No	
Room Numbers				
Room No.			Description	
P14.2910			Diagnostic Service Laboratory	
G19.3336			Care Team Station	
Biosafety Level :			BSL2	
Meeting Notes :			The goal of this Phase 2 study is to evaluate the efficacy and safety of KTE X19 in patients with MRD positive B ALL. KTE X19 is an autologous CD19 directed CAR T cell therapy in which a patient's own T cells are activated and transduced with an anti CD19 CAR encoded in a replication deficient retroviral vector. The modified cells are then expanded and infused to eliminate CD19 expressing leukemic cells with the aim of eradicate minimal residual disease. IRB approval is pending.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Sarina Anne Piha-Paul	
Document No. :			RM00008659-RN00	
NIH Guidelines Category :			III-C-1.	
Agents :				
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
		No		
Room Numbers				
Room No.			Description	
ACB4.1503			Treatment/ Examination Service	
B1.4392A			Pharmacy	
R2.2315			Pharmacy	
R1.1010			Healthcare Treatment/Examination	
B1.4409A			Pharmacy	
ACB8.2043			IV Prep Room (Pharmacy)	
Biosafety Level :			BSL2	
Meeting Notes :			This clinical study is a Phase 1, open-label, single-agent, single-arm, dose escalation study designed to evaluate the safety and tolerability, and to identify the recommended phase 2 dose of [REDACTED] in patients with advanced solid tumors. [REDACTED] is a genetically modified, attenuated [REDACTED]. The [REDACTED] was engineered to express [REDACTED]. The [REDACTED] will be generated offsite by the sponsor and shipped to MD Anderson for use in patients. IRB approval is pending.	

BSL 2: NEW PROTOCOLS

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	19	0	1	0
Investigator :			Vidya Gopalakrishnan	
Document No. :			RM00001784-RN02	
NIH Guidelines Category :			III-D-3-a.	
Agents :				
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
Lentivirus		No		pGIPZ
Lentivirus		No		phage-Efla-GFP
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
Mouse Neural Progenitor Cells			No	
293T			No	
Brain cancer			No	
Microbial Agents				
Name			Administered to Animals in Vivo	
E. coli k-12			No	
Room Numbers				
Room No.			Description	
MOD1.013a			Tissue Culture Facility	
Biosafety Level :			BSL2	
Meeting Notes :			The PI plans to study the role of ING2 in pediatric brain development and cancers using lentivirus to overexpress or knock down this gene in vitro only. Myc and REST genes are also included in the rDNA section. Mouse and human cell lines will be utilized in this study.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Amer M Najjar	
Document No. :			RM00001078-RN02	
NIH Guidelines Category :			III-D-1-a.	
Agents :				
Non Viral Systems				
Technical Name			Is Whole Animal Used as Host	
pPB			No	
pSB			No	
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
Lentivirus		No		pLV430
Retrovirus		No		MSGV
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
NALM-6 Leukemia			Yes	
Daudi lymphoma cells			Yes	
293METR Human Embryonic Kidney cells			No	
human primary T cells			Yes	
293T Human Embryonic Kidney cells			Yes	
human primary NK cells			Yes	
Jurkat T lymphocytes			No	
OS-17 Osteosarcoma			Yes	
Microbial Agents				
Name			Administered to Animals in Vivo	
E coli DH10B			No	
Room Numbers				
Room No.			Description	
MOD1.027A			Tissue Culture Facility	
PPB1.645			Animal Facilities	
Biosafety Level :			BSL2	
Meeting Notes :			In this protocol, immune cells transduced with viral and non-viral systems to express chimeric antigen receptor genes, reporter genes, and T cell receptor NY-ESO1 will be infused in NSG mice bearing tumors to determine antitumor activity by fluorescence and bioluminescence imaging. Human primary NK and T cells will be utilized in this study, as well non-primary cell lines. IACUC and IRB protocols are current.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0
Investigator :			Li Ma	
Document No. :			RM00000621-RN03	
NIH Guidelines Category :			III-D-4-b.	
Agents :				
Non Viral Systems				
Technical Name			Is Whole Animal Used as Host	
pT3-EF1a-GFP-miRE transposon vector			Yes	
ITGB4-luc			No	
pT3-EF1a-GFP-miRE-shRen			Yes	
pT4-CMV-GFP			Yes	
CMV-SB2			Yes	
pT3-EF1a-N-RasG12V			Yes	
pDONR201			No	
pGL3-Basic			No	

BSL 2: NEW PROTOCOLS**Non Viral Systems**

pT3-EF1a-YAP127A	Yes
pCMV-Sport6	No
pRK5-HA	No
pT2/SVNeo	Yes
pT3-EF1a-MYC-IRES-GFP	Yes
pcDNA3.1	No
pT3-EF1 α -HA-myr-AKT-IRES-Luciferase	Yes
pT3-EF1a	Yes
pT3-EF1a-MYC	Yes
pT3-EF1a-AKT	Yes
pT3-EF1a-hmet	Yes
pT3-EF1a-del N90 B-catenin	Yes
CMV-SB13 Transposase	Yes
pCMV(CAT)T7-SB100X	Yes
pCDNA3	No
pDONR221	No
pMir-Luc	No
pT3-EF1aH-GW	No
pLive	Yes

Viral Systems**Virus System**

Virus System	Virus Administered to Animals
lentivirus	No
Retrovirus	No
Adenovirus	Yes
lentivirus	No
Lentivirus	No
Adeno-Associated Virus	Yes
Lentivirus	No

Backbones

pDECKO
 pBABE-puro, pBabe-SFB, pMSCV-PIG, MDH1-PGK-GFP 2.0, MDH1-PGK-GFP, pBABE-hygro
 pShuttle; pShuttle-CMV, pAdtrack; pAdtrack-CMV; Ad5
 LentiCas9-blast; pMH-Flag-HA; pCRISPRia-v2; dCas9-VPR; lentiGuide-Puro
 pmiR-ZIP, pLX304, pGIPZ, pLOC, pFUW, pLenti 6.0, 6.2, 6.3, pLKO-puro, pLenti-CMV-hygro; pLKO.1-Blast; LentiCRISPR v2; FU-MCS-CRW/RFP;pCDH lentiviral vectors;
 AAV8-GFP-U6
 pCDCAR1 GPC3.BBZ.CAR

Cell Lines**Cell Line**

Cell Line	Cell Lines Administered to Animals in Vivo
Lymphoma	No
Embryonic Kidney cells	No
Lung cancer	Yes
liver cancer	Yes
liver cancer	Yes
Embryonic Fibroblasts	No
prostate cancer	Yes
mammary epithelial	Yes
pancreatic cancer	No
Colon Cancer	No
pancreatic cancer	Yes
Cervical Cancer	No
Breast cancer	Yes
Breast cancer	Yes
Bone Cancer	Yes
Leukemia	Yes
CD8+ T cells	Yes
CD8+ T cells	Yes
prostate cancer	No
melanoma	Yes
melanoma	Yes
Lung cancer	No
colon cancer	Yes
Glioblastoma	Yes

Microbial Agents**Name**

E.Coli (DH5a, DH10B, BL21)

Administered to Animals in Vivo

No

Room Numbers**Room No.**

Z7.2041
 Z7.2036
 S1.8234
 SB.8272
 Z1.5014
 Z7.2039
 Z7.2037A
 SB.8240
 Z7.2037B
 SB.8256
 Z7.2038

Description

Cold Room/Walk-in
 Research/Non-Class Laboratory- Wet Lab
 Animal Facilities
 Animal Facilities
 Animal Quarters Service
 Chemical Fume Hood Room
 Flex Wet Lab
 Animal Facilities
 Tissue Culture Facility
 Animal Facilities
 Research/Non-Class Laboratory- Wet Lab
 BSL2

Biosafety Level :

Meeting Notes :

The goal of the research is to understand mechanisms of tumor progression and metastasis in diverse cell types. Recombinant DNAs will be used to achieve either overexpression, knockdown or knockout of specific genes, which include genes for proteins, microRNAs, and other non-coding RNAs. The work will be performed both in vitro and in vivo, with human and mouse cell lines, and viral and non-viral agents being injected in mice. IACUC protocol is current.

BSL 2: NEW PROTOCOLS

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Amer M Najjar	
Document No. :			RM00001062-RN02	
NIH Guidelines Category :			III-D-1-a.	
Agents :				
Non Viral Systems				
Technical Name			Is Whole Animal Used as Host	
pSBSO, PT-MNDU3, pSBSO-FRA, pSBSO-SIM			No	
pKan-CMV-SB11,pCMV-SB11,SB100x, hSB81, hSB110,			No	
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
Lentivirus		No		pHIV, pLenti, pLVX, pLVU3GeffLuc-T2AmKates158A
Retrovirus		No		SFG, MSGV1
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
Osteosarcoma Cell Lines (OS-17, M17, SJSA1, SaSO2, CCH-OS-O, MG63.2)			Yes	
Pancreatic cancer cell lines (3.014_Pa28C, JD13D_Pa04C, A2.1 N9, Panc198_Pa20C, Panc10.05_Pa16C, A6C P29, 8.13, 5.04 P25, Pa01C, Pa02C, Pa03C, Pa04C, Pa14C, Pa16C)			Yes	
human primary T cells			Yes	
U87 glioma cells			No	
A431 skin epidermis cells			Yes	
Kasumi acute myeloblastic leukemia cells			Yes	
LN18 Human glioma cells			Yes	
T98G glioma cells			Yes	
K562 Human CML cells			Yes	
Daudi, B cell lymphoma cells			Yes	
EL4 mouse lymphoma cells			Yes	
NALM-6 acute lymphoblastic leukemia cells			Yes	
HEK293T Human embryonic kidney cells			No	
NIH 3T3 Mouse fibroblast cells			No	
Ovarian cancer (A2780)			Yes	
Glioblastoma, U251T			Yes	
Melanoma (A375SM)			Yes	
LM2			Yes	
Breast cancer (MDA-MB-231)			Yes	
ESI-035			Yes	
Small cell lung carcinoma (H526, H524, H841)			Yes	
Neuroblastoma cell lines (CHLA-255, CHLA-136, SK-N-BE (2), SK-N-SH, CHP-134)			Yes	
Microbial Agents				
Name			Administered to Animals in Vivo	
E. coli DH10B			No	
Room Numbers				
Room No.			Description	
PPB1.628			Animal Imaging	
PPB1.643			Animal Facilities	
PPB1.645			Animal Facilities	
MOD2.027a			Tissue Culture Facility	
PPB1.644			Animal Facilities	
Biosafety Level :			BSL2	
Meeting Notes :			The objective of this study is to develop T cells genetically modified to express chimeric antigen receptors (CAR) that can recognize CD19 on the surface of B cell leukemia cells. Human primary T-cells will be modified using the sleeping beauty transposon/transposase system, and various cancer cells will be infected with lentivirus for further in vitro and in vivo studies. The modified lines will be administered to animals in vivo. IRB and IACUC protocols are current.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	19	0	1	0
Investigator :			Vidya Gopalakrishnan	
Document No. :			RM00001641-RN02	
NIH Guidelines Category :			III-D-1-a.	
Agents :				
Non Viral Systems				
Technical Name			Is Whole Animal Used as Host	
pcDNA3 Flag TSC2			No	
EMM65/LSD1			No	
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
Lentivirus		No		pGIPZ
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
medulloblastoma cells			No	
293T/human kidney cancer cells			No	
Microbial Agents				
Name			Administered to Animals in Vivo	
E. coli k-12			No	
Room Numbers				
Room No.			Description	
MOD1.013a			Tissue Culture Facility	

BSL 2: NEW PROTOCOLS

Cell Lines

Cell Line

[REDACTED]

Cell Lines Administered to Animals in Vivo

No
Yes
Yes
Yes

Microbial Agents

Name

[REDACTED]

Administered to Animals in Vivo

No
No

Room Numbers

Room No.

SB.8256
S1.8239
SB.8264
S1.8440
T8.3986A
T8.3986

Description

Animal Facilities
Animal Facilities
Animal Quarters Service
Animal Facilities
Tissue Culture Facility
Research/Non-Class Laboratory- Wet Lab
BSL2

Biosafety Level :

Meeting Notes :

This study aims to investigate the effect of [REDACTED] in lung adenocarcinoma which represent major determinants of signaling diversification and how can impact the tumor cells. Viral vectors will be used for gene transfer and editing in vitro and in vivo. IACUC protocols are current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Keila Enitt Torres

Document No. :

RM00001675-RN02

NIH Guidelines Category :

III-D-1-a.

Agents :

Non Viral Systems

Technical Name

pEGFP-N1
pDONR223

Is Whole Animal Used as Host

No
No

Viral Systems

Virus System

lentivirus
lentivirus

Virus Administered to Animals

No
No

Backbones

pGIPZ
pInducer21

Cell Lines

Cell Line

Normal Schwann Cell
293T
Malignant peripheral nerve sheath tumor (MPNST) Sarcoma Cell lines
Breast Cancer
Sarcoma
TIL

Cell Lines Administered to Animals in Vivo

No
No
Yes
No
Yes
Yes

Microbial Agents

Name

NEB Stable
E. coli DH5alpha
E.coli One Shot® ccdB Survival™ 2 T1R Competent Cells
E.coli Stb13

Administered to Animals in Vivo

No
No
No
No

Room Numbers

Room No.

S1.8230
4SCR2.2001
4SCR2.2040
3SCR1.3112
3SCR1.3121
3SCR1.3123
SB.8240
SB.8272
SB.8289
S1.8461
S1.8235

Description

Animal Quarters Service
Tissue Culture Facility
Research/Non-Class Laboratory- Wet Lab
Animal Facilities
Animal Facilities
Animal Facilities
Animal Facilities
Animal Facilities
Animal Facilities
Animal Quarters Service
Animal Facilities
BSL2

Biosafety Level :

Meeting Notes :

The goal of this protocol is to investigate the activity of DNA repair pathways in malignant peripheral nerve sheath tumor (MPNST). Standard plasmids and lentiviral vectors will be used to transduce MPNST and breast cancer cell lines and assess DNA repair function by evaluating the integrity of HR and NHEJ mechanisms in vitro. Genetically modified cell lines will also be injected into mice to determine how alterations in these pathways influence tumor growth and progression. IACUC and IRB protocols are current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Abhijit Mazumdar

Document No. :

RM00008725-RN00

NIH Guidelines Category :

III-D-1-a.

Agents :

BSL 2: NEW PROTOCOLS**Non Viral Systems**

Technical Name	Is Whole Animal Used as Host
pCDNA;	No
pCMVPTK7	No
pUHD;	No
pEGFP;	No
pCMV6-DAPK1	No
pCMV-GFP-MELK	No
pCMV;	No
kinase , phosphatases and transcription factor	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
retro virus	No	pBABE puro
shRNA (against various genes)	No	Lentivirus
retro viral	No	pJP1520
Lenti virus	No	pLNCX

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
293T (human embryonic kidney cell line)	No
BT549, HCC1937, HCC1954, MCF7, MDA 231, T47D, Sum 1459, MDA MB 468, ZR 75-30, BT474, HST 578t, MDA MB 231LM2, HIm6 (p53 Wild type and knock down, WU-BC3(p53 Wild type and knock down), WU BC4, WUBC5 , Cal51, HCC1954, HCC 38, HCC 1143, HCC70, HCC1937, HCC	Yes

Microbial Agents

Name	Administered to Animals in Vivo
E.Coli	No

Room Numbers

Room No.	Description
SB.8252	Animal Facilities
S1.8473	Animal Facilities
S7.8405	Flex Wet Lab

Biosafety Level :

Meeting Notes :

BSL2

The goal of this study is to investigate the roles of kinases, phosphatases, and transcription factors in the development of ER negative breast cancer. The work will involve the use of multiple plasmids, lentiviral, retroviral, shRNA, and siRNA vectors. Several breast cancer cell lines modified with these vectors will be evaluated in vivo using mouse models. Two IACUC protocols are already in place to support this work.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Abhijit Mazumdar

Document No. :

RM00008724-RN00

NIH Guidelines Category :

III-D-1-a.

Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
siRNAs (non viral)	No
pCDNA-Flag (non viral)	No
siRNAs (non viral)	No
CRISPR/Cas9 system (sgRNA constructs)	No
pCMV (non viral)	No
pUHD (non viral)	No
pJP520 (non viral)	No
pCDNA (non viral)	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
retro virus	No	pLNCX
Lentivirus	No	pTRIPZ-shRNA
Lentivirus	No	pGIPZ-shRNA
Lentivirus	No	pTRIPZ, pTRINZ, pTIPZ, pTRIHZ

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Human Embryonic Kidney cell (HEK293)	No
Breast Cancer Cells (BT549, HCC1937, HCC1954, MCF7, MDA MB 231, T47D, Sum 1459, MDA MB 468, ZR 75-30, BT474, HST 578t, MDA MB 231LM2, HIm6 (p53 Wild type and knock down, WU-BC3(p53 Wild type and knock down), WU BC4, WUBC5, HCC1395	Yes

Microbial Agents

Name	Administered to Animals in Vivo
E.Coli (DH5-alpha)	No

Room Numbers

Room No.	Description
S7.8405	Flex Wet Lab
S7.8402	Tissue Culture Facility
SB.8268	Animal Facilities
SB.8256	Animal Facilities

Biosafety Level :

BSL2

Meeting Notes :

The PI plans to study the role of kinases, phosphatases and transcription factors in the development of ER-negative breast cancer using non-viral, retroviral, and lentiviral plasmids. Breast cancer cell lines will be modified using rDNA and administered to animals in vivo. IACUC protocol is current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

BSL 2: NEW PROTOCOLS

Investigator : Tin-Yun Tang
Document No. : RM00008553-RN00
NIH Guidelines Category : III-C-1.
Agents :

Viral Systems
Virus System

Virus Administered to Animals
No

Backbones

Room Numbers

Room No.

R2.2315
ACB8.2043
B1.4409A
ACB4.1503

Description

Pharmacy
IV Prep Room (Pharmacy)
Pharmacy
Treatment/ Examination Service

Biosafety Level :
Meeting Notes :

BSL2
The goal of this Phase I/II study is to evaluate the safety, tolerability, efficacy, and recommended Phase 2 dose of [REDACTED] gene therapy in patients with HER2 positive cancer. The agent is a replication deficient recombinant [REDACTED] that delivers [REDACTED] a bispecific protein that binds HER2 on tumor cells and CD3 on T cells, redirecting T cells to eliminate HER2 positive cancer cells. IRB approval is pending.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :
Document No. :
NIH Guidelines Category :
Agents :

Ecaterina Ileana Dumbrava
RM00008638-RN00
III-C-1.

Viral Systems
Virus System

Virus Administered to Animals
No

Backbones

Cell Lines

Cell Line

[REDACTED]

Cell Lines Administered to Animals in Vivo

No

Room Numbers

Room No.

P14.3063
G18.3433
P14.2910

Description

Diagnostic Service Laboratory
Patient Bedroom
Diagnostic Service Laboratory
BSL2

Biosafety Level :
Meeting Notes :

This clinical protocol is a phase 1 first-in-human study to investigate the safety, pharmacokinetics and preliminary efficacy of [REDACTED], an [REDACTED] therapy, in participants with relapsed/refractory small cell lung cancer or select neuroendocrine carcinomas. IRB approval is pending.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :
Document No. :
NIH Guidelines Category :
Agents :

Isabella Claudia Glitza Oliva
RM00008658-RN00
III-C-1.

Viral Systems
Virus System

Virus Administered to Animals
No

Backbones

Room Numbers

Room No.

R9.2194
ACB8.2043
P2.3082A
B1.4409B
B1.4392

Description

Examination
IV Prep Room (Pharmacy)
IV Prep Room (Pharmacy)
Pharmacy
Multi person office

Biosafety Level :
Meeting Notes :

BSL2
The objective of this Phase 3 clinical study is to determine the performance of [REDACTED] in combination with Nivolumab in the treatment of patients with advanced melanoma, in comparison to standard therapies. [REDACTED] is a genetically modified [REDACTED] engineered to selectively replicate in and kill cancer cells. Live viruses will be manufactured offsite and shipped to MD Anderson for administering in patients. IRB contingencies include the clarification of the current PI as it has been reassigned more than once.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :
Document No. :
NIH Guidelines Category :
Agents :

May Daher
RM00004926-RN01
III-D-1-a.

Non Viral Systems

Technical Name

NR3C1 gRNA and Spyfi Cas9

Is Whole Animal Used as Host

No

Cell Lines

Cell Line

Virus specific T cells

Cell Lines Administered to Animals in Vivo

No

Room Numbers

Room No.

P14.2910

Description

Diagnostic Service Laboratory

BSL 2: NEW PROTOCOLS

Biosafety Level :
Meeting Notes :

BSL2

The goal of this project is to knockout the glucocorticoid receptor (GR) in virus specific T cells using CrisPR/Cas9. Once developed and validated, such cells can be utilized to treat patients with viral infections who are immunosuppressed and receiving glucocorticoid therapy. Only in vitro studies are planned. Correct continuing IRB review memo needs to be uploaded to the registration.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Sairah Ahmed	
Document No. :			RM00008704-RN00	
NIH Guidelines Category :			III-C-1.	
Agents :				
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
gammaretrovirus		No		pMD2.G
Cell Lines				
Cell Line			Cell Lines Administered to Animals in Vivo	
Allogeneic T Cells			No	
Room Numbers				
Room No.			Description	
P14.3140			Diagnostic Support Laboratory Service	
R8.2400			Public Corridor	
P14.2910			Diagnostic Service Laboratory	
G15.3433			Patient Bedroom	
Biosafety Level :			BSL2	
Meeting Notes :			This trial evaluates the clinical efficacy of allogeneic CAR-T cell targeting CD19 and CD20 in the treatment of B-cell malignancies. Retroviral system from commercial source will be used to modify normal donor derived T-cells, with production of the CAR-T agent done at the sponsor's manufacturing site outside MD Anderson. IRB approval is pending.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Johannes Francois Fahrmann	
Document No. :			RM00008697-RN00	
NIH Guidelines Category :			III-D-1-a.	
Agents :				
Non Viral Systems				
Technical Name			Is Whole Animal Used as Host	
pFN-CadA-KO			No	
pFN-GFP reporter plasmid			No	
Microbial Agents				
Name			Administered to Animals in Vivo	
Fusobacterium Nucleatum			Yes	
Room Numbers				
Room No.			Description	
SB.8277			Animal Facilities	
SB.8276			Animal Quarters Service	
Biosafety Level :			BSL2	
Meeting Notes :			The goal of this study is to investigate whether microbial-derived cadaverine serves as a parallel source of mammalian polyamines to promote malignant progression of PDAC precursor lesions and to modulate the tumor-immune microenvironment. Furthermore, this study is to test whether targeting cadaverine-producing bacteria combined with eflornithine represents a promising interception strategy. CadA-KO or wild-type GFP-labeled F. nucleatum bacteria will be generated with plasmid vectors and PDAC pancreatic cancer mouse model will be used. IACUC amendment is needed to add the administration of F. nucleatum to mice.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Sarina Anne Piha-Paul	
Document No. :			RM00008565-RN00	
NIH Guidelines Category :			III-C-1.	
Agents :				
Viral Systems				
Virus System		Virus Administered to Animals		Backbones
[REDACTED]		No		[REDACTED]
Room Numbers				
Room No.			Description	
B1.4409A			Pharmacy	
ACB8.2043			IV Prep Room (Pharmacy)	
ACB4.1503			Treatment/ Examination Service	
R2.2315			Pharmacy	
Biosafety Level :			BSL2	
Meeting Notes :			This trial is a First-in-human, open-label, non-randomized, dose escalation trial evaluating the safety, tolerability, early efficacy signals and recommended dose for [REDACTED] administered as monotherapy and in combination with an anti-PD-1 mAb. [REDACTED] is an [REDACTED] therapeutic agent. IRB approval is pending.	

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0
Investigator :			Ju-Seog Lee	
Document No. :			RM00008734-RN00	
NIH Guidelines Category :			III-D-1-a.	

BSL 2- NEW PROTOCOLS

Agents :

Viral Systems**Virus System**

Lentivirus

Lentivirus

Virus Administered to Animals

No

No

Backbones

lentiCRISPR v2

pCDH-EF1-MCS-T2A-Puro, pLenti-DEST

Cell Lines**Cell Line**

Mouse breast cancer cells

human embryo kidney cell 293T

Human ovarian cancer cells

Human breast cancer cells

Cell Lines Administered to Animals in Vivo

Yes

No

Yes

Yes

Microbial Agents**Name**

Ecoli Stb13 strain

Administered to Animals in Vivo

No

Room Numbers**Room No.**

Z10.2031B

S1.8473

Biosafety Level :

Meeting Notes :

Description

Tissue Culture Facility

Animal Facilities

BSL2

The PI plans to study the role of glutamine synthetase in cancer cell dormancy and resistance to cell death. GS expression will be manipulated in cell lines using recombinant DNA-based approaches. GS-overexpressed or GS-depleted cancer cells will be transplanted into immunodeficient mice, to monitor primary tumor outgrowth and to model disseminated disease and dormancy. IACUC protocol is current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Sankaranarayanan Kannan

Document No. :

[RM00008726-RN00](#)

NIH Guidelines Category :

III-D-1-a.

Agents :

Non Viral Systems**Technical Name**

Nucleotides

Is Whole Animal Used as Host

No

Viral Systems**Virus System**

Retrovirus

Virus Administered to Animals

No

Backbones

MSCV

Cell Lines**Cell Line**

BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)

Cell Lines Administered to Animals in Vivo

Yes

Room Numbers**Room No.**

S1.8464

Biosafety Level :

Meeting Notes :

Description

Animal Facilities

BSL2

The PI aims to demonstrated that reduced TXNRD1 expression is important for drug resistance in Blastic plasmacytoid dendritic cell neoplasm, and to determine its interaction with TET2 gene in regulation of the disease. BPDCN cell line will be modified using CRISPR-Cas9 and retrovirus system and administered to animals in vivo for further cellular and molecular studies. IACUC protocol is current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Ashley Makela

Document No. :

[RM00008695-RN00](#)

NIH Guidelines Category :

III-D-1-a.

Agents :

Non Viral Systems**Technical Name**

Synthetic mRNA encoding reporter genes (e.g., GFP, firefly luciferase) or chimeric antigen receptors (e.g., CD19 CAR)

Is Whole Animal Used as Host

Yes

Viral Systems**Virus System**

Retrovirus

Virus Administered to Animals

No

Backbones

pRetro and SFG

Cell Lines**Cell Line**

Human T cell

Non-primary murine T cell

Primary mouse T cells

Cell Lines Administered to Animals in Vivo

Yes

No

Yes

Room Numbers**Room No.**

3SCR1.3114

3SCR2.4405

Biosafety Level :

Meeting Notes :

Description

Animal Facilities

Tissue Culture Facility

BSL2

This protocol focuses on developing and evaluating methods for engineering T cells to improve their ability to recognize and target cancer cells. Mouse T cells and commercially sourced human T cells will be engineered to express CARs. mRNA lipid nanoparticles and retroviral vector will be used to engineer T cells. The modified cells will be injected in mice and then tracked in vivo using noninvasive imaging. IACUC protocol is current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Chunru Lin

BSL 2: NEW PROTOCOLS

Document No. : [RM00001787-RN02](#)
 NIH Guidelines Category : III-D-4-b.

Agents :

Viral Systems**Virus System**

Adeno-associated virus
 vesicular stomatitis virus (VSV)
 Adeno-associated virus
 Adenovirus-Cre
 Lentivirus

Virus Administered to Animals

Yes
 No
 Yes
 Yes
 Yes

Backbones

AAV8
 pRP-VSV-EGFP
 AAV9
 Human Adenovirus Type5
 pLenti

Cell Lines**Cell Line**

bladder cancer cell
 Mouse Breast Cancer E0771 Cancer Cell Line
 Human 293T cells
 breast cancer
 Mouse B16 Cancer Cell Line
 keratinocyte - non human
 pancreatic cancer cell
 lung epithelial cells - non human
 mouse embryonic fibroblasts (MEFs)
 human normal epithelial cell
 bladder cancer cell
 Mouse MC38 colon cancer cell

Cell Lines Administered to Animals in Vivo

Yes
 Yes
 No
 Yes
 Yes
 No
 No
 No
 No
 Yes
 Yes

Room Numbers**Room No.**

Z11.4019
 SB.8209
 Z11.4023
 Z11.4026
 S1.8440

Description

Tissue Culture Facility
 Animal Facilities
 Chemical Fume Hood Room
 Research/Non-Class Laboratory- Wet Lab
 Animal Facilities

Biosafety Level :

BSL2

Meeting Notes :

The goal of this project is to investigate the potential roles of noncoding RNAs, including PVT1 in breast cancer, pancreatic cancer, and bladder cancer tumorigenesis. Agents include replication incompetent viral vectors that will be used in association with a variety of cell lines and rDNAs. Cell lines and viral vectors with rDNAs will be administered to animals in vivo. IACUC protocols are current.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	19	0	1	0

Investigator :

Vidya Gopalakrishnan

Document No. :

[RM00008708-RN00](#)

NIH Guidelines Category :

III-D-1-a.

Agents :

Viral Systems**Virus System**

Lentivirus

Virus Administered to Animals

No

Backbones

SMARTvector hEF1a-TurboRFP

Cell Lines**Cell Line**

Medulloblastma-Daoy, UW228, UW426, ONS-76
 Embryonic kidney 293T cell

Cell Lines Administered to Animals in Vivo

Yes
 No

Microbial Agents**Name**

E.coli-DH5alpha

Administered to Animals in Vivo

No

Room Numbers**Room No.**

MOD1.014
 PPB1.437
 MOD1.013a
 MOD1.012

Description

Research/Non-Class Laboratory- Wet Lab
 Animal Facilities
 Tissue Culture Facility
 Research/Non-Class Laboratory- Wet Lab

Biosafety Level :

BSL2

Meeting Notes :

This study is to evaluate whether PCM1 gene knockdown will suppress the growth of childhood medulloblastoma. SHH MB cell lines will be infected with lentiviral particles with doxycycline-inducible PCM1 shRNA. These inducible shPCM1 cells, along with matched controls, will then be implanted intracranially into NSG mice, where PCM1 suppression will be triggered via doxycycline chow, allowing longitudinal assessment of tumor burden by MRI and subsequent survival analysis. Harvested tumors will be characterized using cellular and molecular assays. IACUC protocol is current.

BSL 3: NEW PROTOCOLS

There are no new protocols to review for this meeting.

7. MODIFICATIONS WITH NEW BSL2/BSL3 AGENTS/PROCEDURES/PI CHANGE

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Ju-Seog Lee

Document No. :

[RM00003140-RN01_AM1](#)

NIH Guidelines Category :

III-D-1-a.

Agents :

Viral Systems**Virus System**

Lentivirus

Virus Administered to Animals

No

Backbones

pCDH-EF1-MCS-T2A-Puro, pLenti-DEST

Microbial Agents

CJRB-101 (Enterococcus gallinarum)

Yes

Biosafety Level :

BSL2

Meeting Notes :

Amendment includes use of CMV-Cre-RFP virus and added human and mouse cell lines to the study.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Christopher Alvarez-Breckenridge

Document No. :

RM00006080-RN00_AM10

NIH Guidelines Category :

III-D-4-b.

Agents :

Non Viral Systems**Technical Name**

pCMV-VSV-G
 mRNA mix with nanoparticles
 pCMV-dR8.91

Is Whole Animal Used as Host

No
 Yes
 No

Viral Systems**Virus System**

adenovirus
 Lentivirus

Virus Administered to Animals

Yes
 No

Backbones

Delta-24 backbone (mutation of 24bp in E1A)
 pCDH-CMV-Firefly Luciferase-EF1-CopGFP

Cell Lines**Cell Line**

Peripheral blood mononuclear cells
 Chordoma cells
 Osteosarcoma cells
 GP100 specific T cell (irrelevant T cells)
 M27 specific T cell (irrelevant T cells)
 lung cancer cells
 Lung cancer cells
 Renal cancer
 Breast cancer
 melanoma cells
 Prostate cancer
 Breast cancer
 Prostate cancer
 Parental brachyury specific T cells
 CAR-NK
 Chordoma cells
 293T
 Renal Cancer
 Brachyury specific TCR engineered T cells
 Brain metastases tissue
 Spine primary and metastatic tumor tissue

Cell Lines Administered to Animals in Vivo

No
 No
 Yes
 Yes
 Yes
 Yes
 Yes
 Yes
 Yes
 No
 Yes
 Yes
 Yes
 Yes
 Yes
 Yes
 No
 Yes
 Yes
 No
 No

Microbial Agents**Name**

E. coli (DH5a)

Administered to Animals in Vivo

No

Biosafety Level :

BSL2

Meeting Notes :

This amendment added CAR-NK and mRNA vaccination as combinatorial treatment strategies in animals in vivo.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Guocan Wang

Document No. :

TA00002415-RN01_AM12

NIH Guidelines Category :

III-F-8.

Agents :

Species**ACUF#**

Mouse 00001713-RN03

Genes Inserted

Pb-Cre4, LSL-Luc, LSL-ERG, mTmG, EGFP, TMPRSS2-CreERT2, TRAMP, Upk2-Cre

Genes Deleted

Pten, Smad4, Yap1, p53, Rb1, Taz, Snf5, Kdm4a, Kdm4b, Kdm4c, Kdm4d, Arid1a, Chd7, Acod1

Biosafety Level :

Meeting Notes :

Updated IACUC protocol number due to renewal.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Francois Villinger

Document No. :

RM00008241-RN00_AM4

NIH Guidelines Category :

III-D-4-b.

Agents :

Viral Systems**Virus System**

pInv-SIVsc/VSV-G

Virus Administered to Animals

Yes

Backbones

SIV under pInv promoter (Nef deleted)

Microbial Agents**Name**

SHIV-1157ipd3N4, SHIV IELp3, SHIV C109, SHIV KN1144, SHIV 162p3, SHIV AD8EO, SHIV CH505, SHIV-RT SIV

Administered to Animals in Vivo

Yes
 Yes

Biosafety Level :

BSL2

Meeting Notes :

An additional IACUC protocol has been linked to the IBC registration. BSL2+ required to account for the risks associated with SHIV & SIV.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
-------------	-----------	---------------	---------------	--------------

Approved 20 0 0 0

Investigator : William J Ray
 Document No. : RM00005890-RN00_AM4
 NIH Guidelines Category : III-D-4-b.
 Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
SCD1-Myc-DDK	No
SCD5-GFP	No
SCD1-GFP	No
SCD5-Myc-DDK	No
pEGFP-C1	No
pcDNA3.1	No
pCMV6-Entry	No
NanoLuc Fusion Vector	No
pCMV6-GFP	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pInducer20, pLIX_403, pLenti-TET-Indu-CMV, pCDH-CMV-MCS-EF1a-puro, pCDH-CMV-MCS-EF1a-BSD, Pires-Puro2
Adeno-associated virus (AAV)	Yes	AAV-PHPeB

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
HEK293T A53T aSyn CFP/YFP cell line	No
WT HeLa Cells	No
U937 myeloid leukemia cells	No
THP-1 leukemia cells	No
L929 fibroblast cells	No
A549 lung carcinoma cells	No
HEK293 kidney cells	No
SIM-A9 microglial cells	No
SCD1 KO HeLa Cells	No
ReNcell CX Neural Progenitor Cell Line	No
Human Astrocytes	No
BV2 microglial cells	No
HEK293T kidney cells	No
H4 neuroglioma cells	No

Microbial Agents

Name	Administered to Animals in Vivo
E. Coli [commercial strains]	No
Biosafety Level :	BSL2
Meeting Notes :	In the amendment, IACUC has been updated.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Lawrence Kwong
 Document No. : RM00002361-RN01_AM6
 NIH Guidelines Category : III-D-1-a.
 Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pX330	No
pT3	Yes
pHIT60, pVSVG	No
psPax2, pMD2.G	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Retrovirus	No	pBabe, pLENC
Lentivirus	No	pLenti6.3; pLKO.1; pHAGE; pLentiCrisprv2; pLIX-403; and other lentiviral vectors

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Melanoma	Yes
293T	No
Melanoma	Yes
Lung immortalized normal cells	Yes
Bladder carcinoma	Yes
Melanoma	Yes
Lung carcinoma	Yes
Melanoma	Yes
Cholangiocarcinoma	Yes

Microbial Agents

Name	Administered to Animals in Vivo
e coli dh5a	No
Biosafety Level :	BSL2
Meeting Notes :	Added two lentiviral backbones and updated personnel.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Joseph A Ludwig

Document No. :
NIH Guidelines Category :
Agents :

RM00006755-RN00_AM3
III-D-1-a.

Viral Systems

Virus System

Lentivirus LT3GEPiR
Lentivirus
Lentivirus

Virus Administered to Animals

No
No
No

Backbones

pRRL
pLV
pScribe5-EFS-Venus-2A-Puro-bc

Cell Lines

Cell Line

Ewing sarcoma
HEK293T
Desmoplastic small round cell tumor (DSRCT)

Cell Lines Administered to Animals in Vivo

Yes
No
Yes

Microbial Agents

Name

E. Coli DH5a
Biosafety Level :
Meeting Notes :

Administered to Animals in Vivo

No
BSL2
Add a lentiviral system to the protocol.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :

Yuan Pan

Document No. :

RM00005849-RN00_AM62

NIH Guidelines Category :

III-D-4-b.

Agents :

Non Viral Systems

Technical Name

[Redacted]

Is Whole Animal Used as Host

No
No
No
No

Viral Systems

Virus System

[Redacted]

Virus Administered to Animals

Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
Yes
No
No
No
Yes
Yes
No
No
Yes
Yes
No
Yes
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
No
No

Backbones

[Redacted]

Cell Lines

████████████████████	Yes
████████████████████	Yes
████████████████████	No
████████████████████	No
████████████████████	No
████████████████████	Yes
████████████████████	Yes

Microbial Agents

Name	Administered to Animals in Vivo
██████████	No
Biosafety Level :	BSL2
Meeting Notes :	Amendment adds 16 ██████████ for multiple genes, added both mouse and human ██████████ cell lines, and changed two IACUCs to new approved versions.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Ronald A DePinho
Document No. : RM00000627-RN02_AM17
NIH Guidelines Category : III-D-1-a.
Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pORF9	No
pBluescript KS(-), pBluescript II sk+	No
pCAG-pBase	No
pUC Ori vector (PX330, PX260, PX334)	No
pCMV, PCMV deltaR8.74, pCMV5, pCMV6	No
pGL4	No
pTTQ18 (pAKTaq)	No
pENTR223	No
pCDNA, pCDNA3, pCDNA3.1	No
pTRE-Tight	No
pMGL	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	NY-ESO-1 TCR, pLenti, pTomo, pCCL-cppt-PGK-WPRE
Lentivirus	No	pLV-CMV51-Halo-ARAF, R747-M61-663, pLenti, CRISPR/ Cas9, pLentiCRISPRv2, SMARTvector
Retro	No	pBabe, pWZL, pMSCV, MSGV-1-1G4 backbone
Lentivirus/ shRNA	No	pLX304-V5, pHAGE-EF1a, pLKO, pLKO.1, pRDA_174, pRDA_550, pLenti6.3, pLenti4, pLKO.3G, pHAGE, pLVX
Lentivirus/packaging virus	No	pRSV-Rev, pMD2.G, pMD-VSVG; pAX2

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Prostate cell lines derived from metastatic sites (DU145, LNCAP, PC3, PC3M, VCAP)	Yes
Colon cancer cell lines (iAP, iKAP)	Yes
Pancreatic cancer cell lines (iKPC, KPC)	Yes
Human endothelial cell lines	No
Embryonal kidney cell lines (293T, 293FT)	No
Colon cancer cell lines (HT-29, SW-480)	Yes
Melanoma cell lines (M407, A375)	Yes
Prostate cancer cell lines (DX1, PPS, MSKPCa1, MSKPCa2, MSKPCa7)	Yes
Mouse Embryonic Stem Cells	No
Lung derived from metastatic sites (e.g., H2052, H2B)	No
APOE3- & APOE4-iPSC-derived neurons and astrocytes	No
Pancreatic cancer cell lines (BxPC-3, PK 59)	Yes
Fibroblast cell lines	No

Microbial Agents

Name	Administered to Animals in Vivo
HB101 E. coli	No
E. coli strain 1677	No
Biosafety Level :	BSL2
Meeting Notes :	The amendment added two new plasmids and melanoma cell lines to the protocol.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Wen Jiang
Document No. : RM00006090-RN00_AM11
NIH Guidelines Category : III-D-4-b.
Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
Entry vector - pNC	No
mRNA that transcribes the CAR gene	Yes
mRNA that transcribes the PIB (PU.1, IRF8, and BATF3) gene	Yes

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pLVX-EF1alpha, with helper plasmids VSV-G, psPAX2, pMDLg/pRRE, pMD2.G, pRSV-REV
Adeno-associated virus	Yes	pAAV

Viral Systems		
Lentivirus	Yes	pRRL with helper plasmids VSV-G, psPAX2, pMDLg/pRRE, pMD2.G, pRSV-REV
Lentivirus	No	pEF-I-GFP-GX with helper plasmids VSV-G, psPAX2, pMDLg/pRRE, pMD2.G, pRSV-REV
Adenovirus	No	pBR322

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
T cells	Yes
Macrophages	Yes
293T	No
Brain tumor cells	Yes
Breast cancer cell	Yes
Peripheral blood mononuclear cell	No
Macrophages	Yes
Biosafety Level :	BSL2
Meeting Notes :	In the amendment, new CAR mRNA has been added to the protocol.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Jason Schenkel
Document No. : RM00006304-RN00_AM7
NIH Guidelines Category : III-D-4-b.
Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
Cre-Luciferase-Ova-SIY	No
Cre-Mscarlette-pRpl18-P2A-Mo-TFR-WT-pltgb1-4x MirT	No
FlpO-mScarlette-pRpl18-4x MirT-Stk11	No
FlpO-mScarlette-pRpl18-4x MirT-Cdh1	No
FlpO-mScarlette-pRpl18-4x MirT-mir200c	No
Cre-Mscarlette-pRpl18-P2A-Mo-TFR-Mut-pltgb1-4x MirT	No
FlpO-mScarlette-pRpl18-4x MirT	No
FlpO-mScarlette-pRpl18-P2A-Mo-TFR-pltgb1-strep-II-4x MirT	No
Sec61b-V5-TurboID	No
Cre-Mscarlette-pRpl18-4x MirT	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-4x MirT Sec61b-V5-TurboID
Lentivirus	Yes	psPax2, pMD2.G, Cre-Mscarlette-pRpl18-P2A-Mo-TFR-WT-pltgb1-4x MirT
Lentivirus	Yes	psPax2, pMD2.G, Cre-Luciferase-Ova-SIY
Lentivirus	Yes	psPax2, pMD2.G, Cre-Mscarlette-pRpl18-4x MirT
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-4x MirT-Stk11
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-4x MirT-Cdh1
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-4x MirT-mir200c
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-4x MirT
Lentivirus	Yes	psPax2, pMD2.G, FlpO-mScarlette-pRpl18-P2A-Mo-TFR-pltgb1-strep-II-4x MirT
Lentivirus	Yes	psPax2, pMD2.G, Cre-Mscarlette-pRpl18-P2A-Mo-TFR-Mut-pltgb1-4x MirT

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Colon cancer	Yes
293T	No
Melanoma	Yes

Microbial Agents

Name	Administered to Animals in Vivo
E.coli Stbl3	No
Biosafety Level :	BSL2
Meeting Notes :	Updated IACUC protocol number due to renewal.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Pavlos Msaouel
Document No. : RM00008300-RN00_AM2
NIH Guidelines Category : III-D-4-b.
Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCMV-DTRcAl-Luc	No
H2B-mCherry Plasmid	No
pEGFP-	No
pGEX	No
pCDNA	No
pCMV-GIP-DTR	No
pCMV-DTRcAl-Red	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Adeno-associated virus	Yes	pAAV-Flex, PD43

Viral Systems

Lentivirus	No	pLenti-PGK-Venus
Adenovirus	Yes	pEMS2158 (AAV9 SEROTYPE)
Adenovirus	Yes	Ad5CMVCre-eGFP
Lentivirus	No	pLVX-TetOne
Lentivirus	No	LentiCRISPRV2
Lentivirus	No	pLv-Puro EF1A
Lentivirus	No	pLenti 4, pLenti 6, pLenti 6.3; pLenti 7.3, pCMV, pBabe-Puro, pTripz, pGipz, pLKO, pLentiCMV, pLKO.1;pHAGE; pRS116, pFUGW based; pCDH, LentiCrispr-V2-GFP; pLSM5
Lentivirus	No	pLKO.1

Cell Lines**Cell Line**

RMC Cell lines (Kidney Cancer)	Yes	Cell Lines Administered to Animals in Vivo
MSRT1 (Kidney Cancer)	Yes	
Vhl-Trp53-Pten-Cdkn2a-Cdkn2b Mouse Cell Line (Kidney Cancer)	Yes	
293T helper Cells	No	
FhKO9p21.3del Mouse Cell line (Kidney Cancer)	Yes	

Microbial Agents

Name	Administered to Animals in Vivo
E. Coli [BL21, BL21star, BL-21 (A-1), HMS 174, Rosetta, and similar commercial strains]	No
Biosafety Level :	BSL2
Meeting Notes :	Added a room to the research facilities list.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :	Guocan Wang
Document No. :	RM00002407-RN01_AM20
NIH Guidelines Category :	III-D-4-b.
Agents :	

Non Viral Systems**Technical Name**

pCMV, PCMV deltaR8.74, pCMV5, pCMV6	Is Whole Animal Used as Host
pBluescript KS(-), pBluescript II sk+	No
pCR3.1 AR-V7	No
pMGL	No
pENTER AR-V7	No
pENTR223	No
pUC Ori vector (PX330)	No
pCDNA, pCDNA3, pCDNA3.1	No
pCAG-pBase	No
ECO-PAK	No

Viral Systems**Virus System**

Lentivirus/packaging virus	Virus Administered to Animals	Backbones
AAV-Cre-GFP	Yes	pRSV-Rev, pMD2.G, pMD-VSVG; pAX2
Lentivirus/shRNA	No	pAAV-MCS
		pLentiRNAguide_002 - hU6-RfxCas13d-DR-BsmBI-EFS-Puro-WPRE, pLentiRNAguide_001 - hU6-RfxCas13d-DR-BsmBI-EFS-Puro-WPRE, piLenti-siRNA & pGIPZ Lentiviral shRNA
Lentivirus	Yes	pHAGE AR-V7, pLEX305_Cterm-dTAG, pLEX305_Nterm-dTAG, PITChv2-BSD-dTAG (BRD4), pCRIS-PITChv2-dTAG-BSD (BRD4), PITChv2-Puro-dTAG (BRD4), pCRIS-PITChv2-dTAG-Puro (BRD4), & pX330A-nBRD4/PITCh
		MIG (MIG-Flag-ER-Hoxb8)
Retrovirus	Yes	pLenti, CRISPR/ Cas9
Lentivirus/ shRNA	Yes	pLenti, pTomo, pCCL-cppt-PGK-WPRE
Lentivirus/ shRNA	Yes	pLenti 6.3-V5/DEST and pLenti4-V5/DEST
Lentivirus/OE	Yes	pLKO.1, pLenti6.3,pLenti4,pLKO.3G,pHAGE, pLVX
Lentivirus/ shRNA	Yes	MSCV (MSCV neo-HA-ER-Hoxb8)
Retrovirus	Yes	pBabe, pWZL, pMSCV
Retrovirus	Yes	pBabe, pQCXIN, pRKO, pEYK, pRRL
Retrovirus	Yes	pLenti6/BLOCK-IT-DEST
Lentivirus/shRNA	No	

Cell Lines**Cell Line**

Chinese Hamster Ovary (CHO-SCF)	No	Cell Lines Administered to Animals in Vivo
Embryonal kidney cell lines (293T)	No	
Prostate cancer cell lines	Yes	
Human NEPC (NCI-H660, LASCPC-1)	Yes	
Mammary gland cell lines (e.g., 4T07, 4T1, HCC1428, HCC1429, HCC1469, HMLE, HS578T,MCF10A)	No	
Urothelial carcinoma (MB49)	Yes	
Prostate cell lines derived from metastatic sites (e.g., DU145, LNCAP, PC3, PC3M, VCAP)	Yes	
Mouse Embryonic Stem Cells	No	
HL 60 (Promyeloblast)	No	
Human endothelial cell lines	Yes	
Mouse Melanoma (B16-GM-CSF)	No	
Lung derived from metastatic sites (e.g., H2052, H2B)	No	
Prostate cancer cell lines	Yes	
Mouse Kidney Cancer Cell Line RENCA	Yes	
Mammary gland cells derived from metastatic sites (e.g., HCC1954, MCF7, MDA-MB231, SKBR3)	Yes	
Human NEPC (144-13)	Yes	
Fibroblast cell lines	No	
Human KidneyCancer Cell Lines 769P, 786O & A498)	Yes	

Cell Lines

Urothelial carcinoma (NHU-Tert, HT1197, HT1376, T24, RT-112,)	Yes
Mouse Myeloid (ER-HoxB8 GMP)	No
Colon cancer cell line (HCT116)	Yes
Urothelial carcinoma (UCC-3, UCC-14, UCC-17, UCC-36)	Yes
Mouse Kidney Cancer Cell Line LVRCC67	Yes
Mouse Bone Marrow (Jedi Bone Marrow)	Yes
Urothelial carcinoma (UPPL1541, BBN963)	Yes
Mouse NEPC (PTR, KPTR)	Yes
Mammary gland ductal carcinoma (e.g., BT459, BT474)	No

Microbial Agents

Name	Administered to Animals in Vivo
DH5a E. coli	No
Biosafety Level :	BSL2
Meeting Notes :	Updated IACUC protocol number due to renewal.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator :	Humam N Kadara
Document No. :	RM00003782-RN01_AM9
NIH Guidelines Category :	NA
Agents :	

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
H2122 human lung cancer cell	Yes
H358 human lung cancer cell line	Yes
H441 human lung cancer cell	Yes

Microbial Agents

Name	Administered to Animals in Vivo
Lactococcus lactis NZ9000	Yes
Lactobacillus acidophilus NCFM	Yes
Escherichia coli Nissle 1917	Yes
Mouse Fecal Microbiota	Yes
Akkermansia muciniphila	Yes
Alistipes finegoldii	Yes
Bifidobacterium animalis subsp. Lactis	Yes
Lactobacillus rhamnensis GG	Yes
Enterococcus faecalis	Yes
Enterococcus faecium	Yes
Bifidobacterium pseudolongum	Yes
Bacteroides sartorii	Yes
Fusobacterium nucleatum (ATCC 25586)	Yes
Porphyromonas gingivalis (ATCC 33277)	Yes
Limosilactobacillus reuteri	Yes
Mycolicibacterium aurum	Yes
Oral Microbiota Transfer	Yes
Biosafety Level :	BSL2
Meeting Notes :	Cell lines for in vivo work have been added, and an IACUC listing the work has been included.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :	Haoqiang Ying
Document No. :	RM00001887-RN01_AM7
NIH Guidelines Category :	III-D-4-b.
Agents :	

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pSL1180	No
ENX-1 CRISPR/Cas9 Knockout plasmid	No
pBR322	No
pCMV	No
pEGFP	No
pGEX	No
pDONR	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	Yes	pLenti6
Lentivirus	Yes	pHAGE
adenovirus	Yes	ad-CMV
retrovirus	No	MSCV
Lentivirus	Yes	pLSM5
Lentivirus	No	pLentiV2
Lentivirus	No	pLKO
retrovirus	No	pBABE

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Colon Cancer	No
T lymphoblast cell line (TALL-104)	No
Mouse pancreatic cancer	Yes
nontumorigenic pancreatic ductal epithelial cells	No

Cell Lines

nontumorigenic fibroblast No
Lung Cancer No
293FT No
Breast Cancer No
Pancreatic Cancer Yes
Sarcoma Yes
OT-I T cells No
OT-II T cells No
melanoma No

Microbial Agents

Name Administered to Animals in Vivo
E. Coli DH5a/BL21/STBL3 No
Biosafety Level : BSL2
Meeting Notes : Updated IACUC protocol number due to renewal.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Luhua Wang
Document No. : RM00005459-RN00_AM13
NIH Guidelines Category : III-D-1-a.
Agents :

Viral Systems

Virus System	Virus Administered to Animals	Backbones
[Redacted]	No	[Redacted]
[Redacted]	No	[Redacted]

Cell Lines

Cell Line Cell Lines Administered to Animals in Vivo
[Redacted] No
[Redacted] Yes
[Redacted] No
[Redacted] Yes
[Redacted] No
[Redacted] No
[Redacted] No

Microbial Agents

Name Administered to Animals in Vivo
[Redacted] No
Biosafety Level : BSL2
Meeting Notes : The amendment adds to experimental plan the investigation of anti-tumor activity of BTK inhibitors alone or combination with [Redacted] and [Redacted] cells in vitro and in vivo. Multiple new agents were added, including [Redacted] and [Redacted], and diverse genes and cell lines.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	20	0	0	0

Investigator : Humam N Kadara
Document No. : RM00008505-RN00_AM1
NIH Guidelines Category : III-D-4-b.
Agents :

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Adeno-associated virus	Yes	Recombinant AAV

Cell Lines

Cell Line Cell Lines Administered to Animals in Vivo
VERO E6 No
KPAR1.3_Lung cancer Yes

Microbial Agents

Name Administered to Animals in Vivo
SARS-CoV-2 Yes
SARS-CoV-2 (MA10 strain) Yes
Biosafety Level : BSL2
Meeting Notes : The amendment adds a strain of SARS-CoV-2 for in vivo experiments, which is referred as mouse-adapted.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	19	0	1	0

Investigator : Guang Peng
Document No. : RM00000645-RN02_AM2
NIH Guidelines Category : III-D-4-b.
Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCMV	No
Plasmids for DNA repair plasmids:mismatch repair plasmids (pmax-vector and derivatives pmax-BFP, pmax-mOrange, pmax-G:G-mismatch-mOrange)	No
peDNA, pCDNA3 and their derivatives (-Flag, -V5, -EGFP)	No
Plasmids for DNA repair: HR repair (DRGFP, I-SceI vecgtors)	No
pEGFP	No

Non Viral Systems

pSL1180	No
pEGFP	No
pCMV	No
pGEX	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
retrovirus	No	MSCV
Lentivirus	No	pLKO
Lentivirus	Yes	pLenti6
Lentivirus	Yes	pHAGE
adenovirus	Yes	ad-CMV
retrovirus	No	pBABE
Lentivirus	Yes	pLSM5
Lentivirus	No	pLentiV2

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
293FT	No
Breast Cancer	No
Mouse pancreatic cancer	Yes
Sarcoma	Yes
OT-I T cells	No
OT-II T cells	No
nontumorigenic pancreatic ductal epithelial cells	No
melanoma	No
Pancreatic Cancer	Yes
Lung Cancer	No
Colon Cancer	No
T lymphoblast cell line (TALL-104)	No
nontumorigenic fibroblast	No

Microbial Agents

Name	Administered to Animals in Vivo
E. Coli DH5a/BL21/STBL3	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Don Lynn Gibbons
Document No. : [RM00000569-RN02_AM6](#)
NIH Guidelines Category :

Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pRL-TK	No
pcDNA5 FRT/TO Flag-BirA R118G [mcs], pcDNA5 FRT/TO [mcs] -BirA R118G Flag	No
pUC19	No
pGL3-mLOXL2 3'UTR	No
pGL3-mLOXL2 Promoter	No
pGL3-Promoter	No
pmRFP-LC3	No
pCR-BluntII-TOPO	No
pCMV5 TrkA	No
pCDNA3.1	No
pGL3-basic	No
pRL-TK	No
pGL3-mLOX 3'UTR	No
hRL	No
pIRES Hyg3	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	Yes	pLenti-Cre GFP miR96
Lentivirus	No	pLenti 4.1
Adenovirus	Yes	Ad5-CMV-Cre
Lentivirus	No	pLKO.1
Lentivirus	No	pCDH-CMV-Puro
Lentivirus	No	pLenti-CMV-GFP-2A-Puro
Lentivirus	Yes	pLL3.3-Cre
Lentivirus	Yes	pLenti-Cre GFP TMEM
Lentivirus	No	pLenti-Puro
Lentivirus	Yes	pLenti-Cre GFP
Retrovirus	No	pGFP-v-RS shRNA
Lentivirus	No	pLenti-EF-ires-blast
Adenovirus	Yes	pAd5
Lentivirus	No	pLV11
Lentivirus	No	miRZip
Lentivirus	No	Tet-pLKO-puro
Lentivirus	No	pLEX4.2
Lentivirus	No	pInducer
Lentivirus	No	pLKO.1-TRC

Viral Systems

Lentivirus	Yes	pLL3.3-Cre-PD-L1
Lentivirus	Yes	pLenti-Cre GFP miR96
Lentivirus	No	pL6.3EF
Lentivirus	No	pLD6.EF-Puro
Lentivirus	No	pTRIPZ
Lentivirus	Yes	pLL3.3-UBC-zSG-PGK-Cre; pLL3.3-UBC-mCherry-PGK-Cre; pLL3.3-UBC-p53-PGK-Cre
Lentivirus	No	Cui-Cas9-sgRNA
Retrovirus	No	pLMP
Lentivirus	No	LV-Cre-pLKO.1
Lentivirus	No	pGIPZ
Lentivirus	Yes	pLenti-Cre-pLKO
Lentivirus	No	pLenti6.3
Adenovirus	Yes	Ad5-CMV-Cre-eGFP

Cell Lines**Cell Line**

Cell Line	Cell Lines Administered to Animals in Vivo
PT67	No
Mouse Lung Cancer Cells	Yes
NIH/3T3 Cells	No
Murine Lung Cancer	Yes
HEK 293T	No
Murine Lung Cancer	Yes
Amphopack293	No
Human Lung Cancer Cells	No

Microbial Agents**Name**

E. Coli DH5a

Biosafety Level :

Meeting Notes :

Administered to Animals in Vivo

No

BSL2

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Eleonora Dondossola

Document No. :

RM00006800-RN00_AM4

NIH Guidelines Category :

Agents :

Non Viral Systems**Technical Name**

Muc1 DeltaCT pPB TetOn IRE

pcDNA3.1-mCherry or HIF-Neptune

Muc1 DeltaCT moxGFP pPB TetOn

pCMV-E2-Crimson

pGL3-Basic Luc

Muc1 DeltaCT moxGFP pPB TetOn rtTA NeoR

pPB TetOn rtTA NeoR

pPB TetOn IRES GFP rtTA NeoR

Is Whole Animal Used as Host

No

Yes

No

Yes

Yes

No

No

No

Viral Systems**Virus System**

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Lentivirus

Virus Administered to Animals

No

No

No

No

No

No

No

No

No

No

No

No

No

No

No

No

Backbones

pLB

pLentiV62V5-DEST w/ cOVA from pCI-neo-cOVA

pLKO

pLVTHM

pLenti6.2-IRES-G1-Orange-S-G2-M-Green

H2B mCherry pLenti6.2v5

pLNCX2-DsRed

pLHCK-EGFP

pLentiV62V5-DEST

pLV rtTA-M2 IRES NeoR

pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro

pBMN-Luc-GFP

rV2.1A1.2187 C2

pLentiV62V5-DEST w/ OVA from pAc-neo-OVA

pLVX-IRES-ZsGreen1

pBMN-Luc-Tomato

Cell Lines**Cell Line**

Fibrosarcoma

Breast Cancer

Osteoblasts

Kidney

Prostate Cancer (PDX)

Melanoma

Prostate Cancer (PDX)

Melanoma

Mesenchymal Stem Cells

Breast Cancer

Cell Lines Administered to Animals in Vivo

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Microbial Agents**Name**

One Shot TOP10 Competent E.Coli

Administered to Animals in Vivo

No

Microbial Agents

Stable3 (Stb13) Competent E.Coli No
 Novablue E.Coli No
 Biosafety Level : BSL2
 Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Florencia McAllister
 Document No. : RM00000874-RN02_AM1
 NIH Guidelines Category :
 Agents :

Viral Systems

Virus System	Virus Administered to Animals	Backbones
adenovirus	Yes	pAdEasy

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
HEK293	No

Biosafety Level : BSL2
 Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Guocan Wang
 Document No. : TA00002415-RN01_AM13
 NIH Guidelines Category :
 Agents :

Species	ACUF#	Genes Inserted	Genes Deleted
Mouse	00001713-RN03	Pb-Cre4, LSL-Luc, LSL-ERG, mTmG, EGFP, TMPRSS2-CreERT2, TRAMP, Upk2-Cre	Pten, Smad4, Yap1, p53, Rb1, Taz, Snf5, Kdm4a, Kdm4b, Kdm4c, Kdm4d, Arid1a, Chd7, Acod1

Biosafety Level :
 Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Michael Spiotto
 Document No. : RM00004440-RN01_AM3
 NIH Guidelines Category :
 Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
SB100x	No
T2/Onc	No
pCAG-LSL-mouseBRD4-NUT1-IRES-LucOS	No
PGK-Cre	No
pCAG-LSL-E6E7-IRES-LucOS	No
pCAG-LSL-humanBRD4-NUT1-IRES-LucOS	No
pCAG-LSL-E6E7-IRES-Luc	No
pcDNA4-TO-pax9	No
pLenti CMV GFP Puro (658-5)	No
pLV-mCherry	No
FUGW ECFP	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Retrovirus	No	MSCV-E6, MSCV-E6F47R, MSCV-E7, MSCV-E7delta21-24, MSCV-E7E26G
Retrovirus	No	MSCV-E6, MSCV-E6F47R, MSCV-E7, MSCV-E7delta21-24, MSCV-E7E26G
Adenovirus	Yes	Human Adenovirus Type5 (dE1/E3) , pAd5PL-DEST-rCGRPCre, G0166 pAd5CMVCreMT1pA, pAd5PL-DEST-mCC10Cre, pAd5PL-DEST-mSPCCre
Lentivirus	No	p156RRL-sinPPT-CMV-GFP-PRE/Nhe I, pLenti-MP2, FUGW
Lentivirus	Yes	pLL3

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Murine melanoma cell lines	Yes
Human keratinocytes	No
Head and neck cell lines	No
Murine fibrosarcoma cell lines	Yes
Phoenix-Ampho	No
Murine lung cancer cell lines	No
Murine oral tumor lines	Yes
Human embryonic kidney cell lines	No
Cervical cancer cell lines	No
murine leukemia cell lines	Yes
Human prostate cancer cell line	No
Human prostate normal cell line	No
Human lung cancer cell lines	No
293T	No
Human liver cancer cell lines	No
Human pancreatic cancer cell lines	No
Murine prostate cancer cell line	Yes

Non Viral Systems**Technical Name**

SB100x
 T2/Onc
 pCAG-LSL-mouseBRD4-NUT1-IRES-LucOS
 PGK-Cre
 pCAG-LSL-E6E7-IRES-LucOS
 pCAG-LSL-humanBRD4-NUT1-IRES-LucOS
 pCAG-LSL-E6E7-IRES-Luc
 pcDNA4-TO-pax9
 pLenti CMV GFP Puro (658-5)
 pLV-mCherry
 FUGW ECFP

Is Whole Animal Used as Host

No
 No
 No
 No
 No
 No
 No
 No
 No
 No

Viral Systems**Virus System**

Retrovirus

Virus Administered to Animals

No

Backbones

MSCV-E6, MSCV-E6F47R, MSCV-E7, MSCV-E7delta21-24, MSCV-E7E26G

Retrovirus

No

MSCV-E6, MSCV-E6F47R, MSCV-E7, MSCV-E7delta21-24, MSCV-E7E26G

Adenovirus

Yes

Human Adenovirus Type5 (dE1/E3) , pAd5PL-DEST-rCGRPCre, G0166 pAd5CMVCreMT1pA, pAd5PL-DEST-mCC10Cre, pAd5PL-DEST-mSPCCre

Lentivirus

No

p156RRL-sinPPT-CMV-GFP-PRE/Nhe I, pLenti-MP2, FUGW

Lentivirus

Yes

pLL3

Cell Lines**Cell Line**

Murine melanoma cell lines
 Human keratinocytes
 Head and neck cell lines
 Murine fibrosarcoma cell lines
 Phoenix-Ampho
 Murine lung cancer cell lines
 Murine oral tumor lines
 Human embryonic kidney cell lines
 Cervical cancer cell lines
 murine leukemia cell lines
 Human prostate cancer cell line
 Human prostate normal cell line
 Human lung cancer cell lines
 293T
 Human liver cancer cell lines
 Human pancreatic cancer cell lines
 Murine prostate cancer cell line
 Murine pancreatic cancer cell lines

Cell Lines Administered to Animals in Vivo

Yes
 No
 No
 Yes
 No
 No
 Yes
 No
 No
 Yes
 No
 No
 No
 No
 No
 No
 No
 Yes
 No

Microbial Agents**Name**

E. coli: DH5-alpha, Stb13

Administered to Animals in Vivo

No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Florencia McAllister

Document No. :

[RM00002365-RN01_AM3](#)

NIH Guidelines Category :

Agents :

Microbial Agents**Name**

Saccharomyces cerevisiae
 Aggregatibacter actinomycetemcomitans
 Kluyveromyces marxianus
 Porphyromonas gingivalis
 Komogataella pastoris

Administered to Animals in Vivo

Yes
 Yes
 Yes
 Yes
 Yes

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

David G Menter

Document No. :

[RM00000264-RN02_AM6](#)

NIH Guidelines Category :

Agents :

Non Viral Systems**Technical Name**

Propagated in rec-deficient E.coli strains
 pGL3 Luciferase and GFP Reporters
 miR RNAi
 Single Vector Inducible RNAi System
 Tet Inducible plasmid
 Tet inducible Expression Systems
 Tet-On Inducible plasmid

Is Whole Animal Used as Host

No
 No
 No
 No
 No
 No
 No

Non Viral Systems

CRISPR/CAS9 knockout (KO) plasmid No

Viral Systems**Virus System**Tet inducible lentivirus
Lentivirus
Adenovirus
lentivirus
Lentivirus**Virus Administered to Animals**No
No
Yes
No
No**Backbones**Tet inducible lentivirus
TRIPZ shRNA lentiviral backbone
Ad-Cre-IRES-GFP human Adenovirus Type5 (dE1/E3)
Lentiviral shRNA vector
Tet inducible lentiviral**Cell Lines****Cell Line**Human Embryonic Kidney 293T Cells
colon patient derived xenografts
Patient derived colon tissue
Lenti-X 293T
colon
colon**Cell Lines Administered to Animals in Vivo**No
Yes
Yes
No
Yes
Yes**Microbial Agents****Name**

E.coli

Biosafety Level :

Meeting Notes :

Administered to Animals in Vivo

No

BSL2

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Document No. :

NIH Guidelines Category :

Agents :

Ronald A DePinho

RM00000627-RN02_AM18

Non Viral Systems**Technical Name**pMGL
pORF9
pUC Ori vector (PX330, PX260, PX334)
pBluescript KS(-), pBluescript II sk+
pENTR223
pTTQ18 (pAKTaq)
pTRE-Tight
pCMV, PCMV deltaR8.74, pCMV5, pCMV6
pCDNA, pCDNA3, pCDNA3.1
pCAG-pBase
pGL4**Is Whole Animal Used as Host**No
No
No
No
No
No
No
No
No
No**Viral Systems****Virus System**Lentivirus/packaging virus
Retro
Lentivirus
Lentivirus**Virus Administered to Animals**No
No
No
No
No**Backbones**pRSV-Rev, pMD2.G, pMD-VSVG; pAX2
pBabe, pWZL, pMSCV, MSGV-1-1G4 backbone
NY-ESO-1 TCR, pLenti, pTomo, pCCL-cppt-PGK-WPRE
pLV-CMV51-Halo-ARAF, R747-M61-663, pLenti, CRISPR/ Cas9,
pLentiCRISPRv2, SMARTvector
pLX304-V5, pHAGE-EF1a, pLKO, pLKO.1, pRDA_174, pRDA_550,
pLenti6.3,pLenti4,pLKO.3G,pHAGE, pLVX**Cell Lines****Cell Line**Prostate cell lines derived from metastatic sites (DU145, LNCAP, PC3, PC3M, VCAP)
Pancreatic cancer cell lines (iKPC, KPC)
Human endothelial cell lines
Embryonal kidney cell lines (293T, 293FT)
Fibroblast cell lines
Melanoma cell lines (M407, A375)
Colon cancer cell lines (iAP, iKAP)
Mouse Embryonic Stem Cells
Pancreatic cancer cell lines (BxPC-3, PK 59)
Prostate cancer cell lines (DX1, PPS, MSKPCa1, MSKPCa2, MSKPCa7)
APOE3- & APOE4-iPSC-derived neurons and astrocytes
Colon cancer cell lines (HT-29, SW-480)
Lung derived from metastatic sites (e.g., H2052, H2B)**Cell Lines Administered to Animals in Vivo**Yes
Yes
No
No
No
Yes
Yes
No
Yes
Yes
No**Microbial Agents****Name**E. coli strain 1677
HB101 E. coli

Biosafety Level :

Meeting Notes :

Administered to Animals in VivoNo
No

BSL2

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator :

Document No. :

NIH Guidelines Category :

Agents :

Kristen Pauken

TA00006318-RN00_AM19

Species**ACUF#****Genes Inserted****Genes Deleted**

Mouse	00002324-RN01	UBC-CreERT2, Ptpcr, Foxp3-GFP	Pdcd1
Mouse	00002403-RN00	Kirtl	
Mouse	00002403-RN00		Ctla4, Pdcd1
Mouse	00002324-RN01	E8i-cre GFP	Pdcd1

Biosafety Level :

Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Albert Koong
Document No. : RM00002797-RN01_AM5

NIH Guidelines Category :

Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
PX458	No
PX459	No
pGL3	No
pcDNA3	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	VSV-G
Lentivirus	No	pLenti
Retrovirus	No	pWZL
Lentivirus	No	pCW
Lentivirus	No	lentiCRISPR v2
Retrovirus	No	pBabe
Lentivirus	No	pLKO.1
Lentivirus	No	Delta 8.2
Lentivirus	No	phDLX1
Retrovirus	No	Gag-Pol
Retrovirus	No	VSVG
Lentivirus	No	pLX
Adenovirus	Yes	Ad5-CMV
Lentivirus	No	pLEX MCS

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Breast Cancer Cell	Yes
Pancreatic Cancer Cell	Yes
Breast cancer	Yes
Multiple Myeloma Cell	Yes
Esophageal Cancer Cell	Yes
Pancreatic Cancer Cell	Yes
Human embryonic kidney (293T)	No
Lung Cancer Cell	Yes
Breast Cancer Cell	Yes
Pancreatic cancer	Yes
Fibrosarcoma Cell	Yes

Microbial Agents

Name	Administered to Animals in Vivo
E. coli	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Ronald A DePinho
Document No. : TA00000781-RN02_AM9

NIH Guidelines Category :

Agents :

Species	ACUF#	Genes Inserted	Genes Deleted
Mouse	00001170-RN03, 00002678-RN00	Zbtb16fl/fl, PD1 Flox, BRAFF-V600E/+, DKK3; PB-Cre; tetO-Kras LSL; Foxo3KI; Kras-LSL; LSL-P53R270H; LSL-P53 R172H; Lgr5-EGFP-CreERT2., OT-I; OT-II; pdx1-cre; Luc Flox; Itgam DTR Tg; Itgas DTR Tg; AFHmter; TetO-Braf; Tg (TeraTerb) Rag 1; GFAP tta; Rosa26-LSL-rtTA-GFP; Rosa-rtTA, Rosa-LSL-Luc; Rosa LSL-LacZ; Rosa LSL YFP; Rosa-CreERT2. , Halo-Sox2; Rosa26 FLPeR, Ptf1a-CreER; p48 Cre; CDX2-CreERT2; CAG-Cre; Syn1-Cre; Rluc-hTERT; R26-CAGGS; pA/R26-CreERT2; pA/3xTg; Nestin-CreERT2; Camk2a-CreERT2; pA/5xFAD; Mdx; P2A-3XFLAG; 3XFLAG; Syn1-CreERT2; 3xTg; 5xFAD; Villin-CreERT2	BRAF F-V600E; CDX2 flox; Lag3 KO; LSL-TERT-ER; mTert KO; mTerc KO; IRS1 Flox; IRS2 Flox; EGFRviii Flox; P16 KO; BAF180 Flox; p19 KO; Kras KO; Apc Flox., HDAC2 Flox; Chd1 tm1a Flox; Chd1 tm1c Flox; Yap1 Flox; PtenERT2; CD8 KO; CD4 KO. , Vg4 KO, Terd KO; PAPSS2 Flox; Msh2 Flox; CDX2 Flox; ATAD1 KO; CCL2/CCL7 DKO; BIRC6 KO. , Sin3a Flox; Sin3b Flox; Ink4a/Arf null; Pten Flox; p53 Flox; Smad 4 Flox.

Biosafety Level :

Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Raghu Kalluri
Document No. : RM00000518-RN02_AM67

NIH Guidelines Category :

Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
----------------	------------------------------

Non Viral Systems

472997: pD2528-CMV-472997	No
pCMV/SB10	No
mouse Tgfb2 donor plasmid	No
PGC1a flag	No
Flag-P53/pRK5	No
pCMV4a-Flag-c-Myc	No
Perk WT	No
pD2528-CMV_QHD43416.1_C-trunc	No
GFP-p53	No
pCMV14-3X-Flag-SARS-CoV-2 S	No
pEGFP-AGO2	No
pcDNA3-RLUC-POLIOIRES-FLUC	No
aSMA-TK	No
mPlum-C1	No
pJKR-H-tetR	No
pD2529-CMV-ACE2_human	No
mouse Gpc1 donor plasmid	No
pPAmCherry1-C1	No
pCMV3-mFCGR2B-t1	No
pD2528-CMV-P.1 Spike Protein	No
nCov-1 nCov-2P-F3CH2S	No
pcDNA3-YFP	No
pCMV6-CD63-GFP	No
pcDNA3.3_mCherry	No
CMV T II Pet 28 Clone	No
tdTomato-C1	No
499328: pD2528-CMV-472997	No
pCMV3-mTNFSF9	No
pDsRed Express 1	No
pMetLuc-Mem Control	No
pFLAG CMV 6A Clones 1-5	No
pCI neo-hEST2-globin mRNA vector	No
pD2528-CMV:499328	No
pT2/Onc	No
pCMV6-Entry	No
pEGFP-n1-APP	No
MCX K11F1 PC BFT	No
pCAG-T7pol	No
pCMV3-untagged	No
PDGFRB-PDsRed	No
aSMA-RFP	No
pFLAG CMV 6A Clone 1 (MD 010508)	No
MMTV-cFos-SV40	Yes
pCMV3-mCD80	No
pDESTmycDicer	No
Drosha WT	No
pRK5-EGFP-Tau P301L	No
a2 PD5 + CAR	No
Drosha-Mut	No
PCMV3-mCD40LG	No
pD2528-CMV_RBD-VSV-G_TM_Chimera	No
mEmerald-CD9-10	No
pDsRed 2-C1	No
CMV ON Col 18 IN PC SPORT 6.1	No
pSpCas9(BB)-2A-Puro (PX459)	No
GPC1	No
pCI neo-hEST2	No
L3L4_pD223_DTA	Yes
mEmerald-CD81-10	No
pRK5-EGFP-Tau E14	No
NG2-YFP	No
pCMV3-C-His_SARS-CoV-2 (2019-nCoV) Spike RBD Gene ORF cDNA clone expression plasmid	No
pMetR-SPECTO	No
human GPC1 donor plasmid	No
pD2528-CMV_B.1.1.526	No
pcDNA3 GFP PTEN	No
pD2528-CMV-B.1.351 Spike protein	No
mouse Smad4 donor plasmid	No
pRK5-EGFP-Tau	No
CAN-Pet 2B Clones 1-4	No
pD2528-CMV-C.37 Spike Protein	No
pD2528-CMV-QHD43416.1_C-trunc_400492	No
TK-TQ 004	No
pcDNA3-CFP	No
NG2-TK	No
pVax1-hVEGF165	No
pCMV3-mCD2	No
pPalmitoyl-mTurquoise2	No
pcBFT-Col 18 TSPN Clone 1	No
gRNA Smad4 mouse target #2 gene knockout plasmid	No
HSP-Cre-IRES	No

Non Viral Systems

pCAS9-guide mouse CD274 donor plasmid	No
FSP 1 II S4P	No
pSpCas9(BB)-2A-GFP (PX458)	No
Oct4 KLF4 Sox2 e-Myc	No
mCherry-CD9-10	No
mouse Pcdcl1lg2 donor plasmid	No
EBFP2-C1	No
pcDNA3.1-CMV-CFP;UBC-Cre25nt	No
pD2528-CMV-QHD43416.1	No
pQC membrane Tdtomato IX	No
Zeb1	No
pIRES2-EGFP-p53 WT	No
pD2528-CMV_RBD-TwinStrep-VSV-G_TM_Chimera	No
pCMV3-CD80	No
pD2529-CMV	No
GGT-SV40	No
pCep. PU	No
pD2528-CMV-B.1.1.526	No
Human GPC-1 overexpression plasmid	No
SARS-CoV-2 spike protein mRNA	Yes
pMetR-ACE2ecto	No
pD2528-CMV-IVT mRNA vector	No
FSP1-GFP	No
pcDNA3 LIC cloning vector	No
T7 PeIB His6	No
PresentER-SIINFEKL (GFP)	No
mCherry-CD81-10	No
PDGFRB-TK -TOPO 11	No
C2 CANSTATIN pc BFT midi	No
pBS18	No
pCMV/SB11	No
pD2528-CMV	No
mCherry-Tsg101	No
pCMV3-CD40LG	No
pT3-N90-beta-catenin	Yes
MtPT4-eGFP	Yes
SB100X in pCAG globin pA	Yes
pT3-EF1A-MYC-IRES-luc	Yes
Perk K618A	No
pD2528-CMV_QHD43416.1_C-trunc-VSV-G-tm	No
ACE2-mFc	No
pCMVTag4-Dicer	No
pD2538-CMV-mVEGF	No
pCAG-mGFP	No
pGL3	No
pcDNA3-OVA	No
pcDNA3-SARS-CoV-2-RBD-8his	No
pD2528-CMV-B.1.617.2 Spike Protein	No
pCMV6-AC-mGFP	No
pEGFP-C1	No
pT/Caggs-NRASV12	Yes
pCMV/SB11	Yes
pT3-myr-AKT-HA	Yes
pCMV-Mark2-tGFP	No
pCMV-Mark3-tGFP	No
pCMV3-C-His_SARS-CoV-2 (2019-nCoV) Nucleoprotein Gene ORF cDNA clone expression plasmid	No
pcBFT Col 18 NCL Clone D	No
pD2528-CMV_RBD-VSV-G_TM_Chimera	No
pcDNA	No
Cerulean-N1	No
PCD FLOX	No
pCMV3-C-GFPSpark-BACE1 cDNA ORF Clone	No
pD2528-CMV_QHD43416.1-VSV-G-tm	No
CANSTATIN Pet 2B	No
pD2529-CMV_ ACE2_human_C-trunc-VSV-G-tm	No
mCherry-hALIX	No
pCMV NYC CRI (MIMI)	No
a2 PD5 (4825Y)	No
pRosa26-DEST	No

Viral Systems**Virus System**

Lentivirus
Lentivirus Particles

Virus Administered to Animals

No
Yes

Baculovirus

Simian immunodeficiency virus (SIV)

No
No

Recombinant vesicular stomatitis virus

Yes

Backbones

pDual-ACE2, pCMV-VSV-G, psPAX2
CRISPR-Cas9-sgVHL, CRISPR-Cas9, pLenti CMV/TO SV 40 small + Large T (w612-1), pLenti-C-mGFP-P2A-Puro, LentiCas9-Blast Plasmid, pLKO.1-puro, CMV-Bsd-CFP
pCMV-Dest
pSIV3, pCMV-VSV-G, psPAX2, pCMV-Luc2-IRES-mCherry, pcDNA3-spike expression
pBS-N-ΦT, pVSV-ΔG-GFP, pVSV-ΔG-Luciferase, pBS-L-ΦT, pCAGGS-G, pcDNA-FLAG-VSVG, pBS-P-ΦT, pD2528-CMV-C.37

Viral Systems

Lentivirus	No	pGIPZ
adenovirus Ad5mSPC-ntcGFP	Yes	pacAd5(9.2-100)sub360 viral backbone
adenovirus Ad5mSPC-FLPo	Yes	pacAd5(9.2-100)sub360 viral backbone.
adenovirus Ad5CMVFLPO	Yes	pacAd5(9.2-100)sub360 viral backbone
Lentivirus	No	pLenti CMV V5-LUC
Ad5-hK14/Bgi-Cre	Yes	pacAd5(9.2-100)sub360 viral backbone

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Lung cancer cell line - 344SQ	Yes
FVBW-17 (gRNA control) - Mouse lung cancer cell-line	Yes
FM471-ctrl-gRNA-GFP/luciferase cells	Yes
293FT cells	No
LKR-13 Luciferase/GFP stable cells - Mouse lung cancer cell-line	Yes
mF471-CD24-gRNA-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13(gRNA control) - Mouse lung cancer cell-line	Yes
FVBW-17 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
Fvbw 17-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13 (Mouse lung cancer cell-line)	Yes
mF471 Luciferase/GFP stable cells - mouse lung cancer cells	Yes
mF471 - mouse lung cancer cells	Yes
LKR-13 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
FVBW-17 cells (Mouse lung cancer cells)	Yes
393P (Mouse lung cancer cell-line)	Yes

Microbial Agents

Name	Administered to Animals in Vivo
Influenza A	Yes
Sendai virus	Yes
DH5a cells	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : Florencia McAllister
Document No. : RM00004900-RN01_AM1

NIH Guidelines Category :

Agents :

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Adeno-associated virus	Yes	pAAV-ApoEHCR and pAAV-MCS.

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
KPC Pancreatic cancer	Yes
MC38	Yes
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : John Paul Shen
Document No. : RM00006505-RN00_AM8

NIH Guidelines Category :

Agents :

Non Viral Systems

Technical Name	Is Whole Animal Used as Host
PX260	No
PX330	No

Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pCMVR8
Lentivirus VB191022-1024bat_R201C	No	pCMVR8
Lentivirus VB191022-1021hef_WT	No	pCMVR8
Lentivirus VB191022-1023nbd_R201H	No	pCMVR8
Lentivirus VB161122-1052kwm	No	pCMVR8

Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Peritoneal mesothelioma	Yes
SW620 colorectal cancer cells	Yes
Patient-derived colorectal cancer cells	Yes
Lung cancer	No
Colorectal cancer cells CRCPDO	Yes
SW837 colorectal cancer cells	Yes
PMCA-3 appendiceal adenocarcinoma cells	Yes
HEK293 human epithelial cells	No
KM12 colorectal cancer cells	Yes
KPC-GNAS pancreatic cells	Yes
Patient-derived appendix cancer cells	Yes
LS174T colorectal cells	Yes
TM00351 appendiceal cancer cells	Yes

Cell Lines

T84 colorectal cancer cells Yes
 Mouse GI cancer cells Yes
 SW1463 colorectal cancer cells Yes
 C479T mouse pancreas cells Yes
 SNU175 colorectal cancer cells Yes
 PMP-2 appendiceal adenocarcinoma cells Yes
 HCT116 colorectal cancer cells Yes
 SW480 colorectal cancer cells Yes
 SKCO1 colorectal cancer cells Yes
 G005T mouse pancreas cells Yes
 Appendix cancer cells AAPDO Yes
 cdx2-cre;KrasG12D;GnasR201C organoids Yes

Microbial Agents

Name **Administered to Animals in Vivo**
 E. coli DH5 α No
 Biosafety Level : BSL2
 Meeting Notes : Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	20	0	0	0

Investigator : May Daher
 Document No. : RM00004926-RN00_AM2
 NIH Guidelines Category :
 Agents :

Non Viral Systems

Technical Name **Is Whole Animal Used as Host**
 NR3C1 gRNA and Spyfi Cas9 No

Cell Lines

Cell Line **Cell Lines Administered to Animals in Vivo**
 Virus specific T cells No
 Biosafety Level : BSL2
 Meeting Notes : Personnel changes only.

9. ANNUAL REVIEWS

20=yes; 0=no; 0-abstain; 0-recuse

Investigator : Juan P Cata
 Document No. : RM00004294-RN01_AR001

Investigator : Robert Orłowski
 Document No. : RM00000367-RN02_AR003

Investigator : Helen Piwnica-Worms
 Document No. : RM00000468-RN02_AR003

Investigator : Cassian Yee
 Document No. : RM00002325-RN01_AR004

Investigator : Rugang Zhang
 Document No. : RM00006497-RN00_AR003

Investigator : Ecaterina Ileana Dumbrava
 Document No. : RM00005643-RN00_AR004

Investigator : Cassian Yee
 Document No. : RM00004423-RN01_AR001

Investigator : Vinay Puduvali
 Document No. : RM00005279-RN00_AR004

Investigator : Georgios Karras
 Document No. : RM00003059-RN01_AR003

Investigator : Maria Morelli
 Document No. : RM00007342-RN00_AR002

Investigator : Joseph A Ludwig
 Document No. : RM00006357-RN00_AR003

Investigator : David Piwnica-Worms
 Document No. : RM00007343-RN00_AR002

Investigator : Kristen Pauken
 Document No. : RM00006570-RN00_AR003

Investigator : John Paul Shen
 Document No. : TA00006445-RN00_AR003

Investigator : Edwin Justin Ostrin
 Document No. : RM00007283-RN00_AR002

Investigator : Marie-Claude Hofmann
 Document No. : RM00003315-RN01_AR002

Investigator : Michael A Davies
 Document No. : RM00008015-RN00_AR001

Investigator : George A Calin
 Document No. : RM00000218-RN02_AR002

Investigator : Xiangsheng Zuo

Document No. :	RM00004560-RN01_AR001
Investigator :	Rugang Zhang
Document No. :	RM00006479-RN00_AR003
Investigator :	Jeffrey J Mollidrem
Document No. :	RM00008139-RN00_AR001
Investigator :	Tina Cascone
Document No. :	RM00007810-RN00_AR001
Investigator :	David Sanghyun Hong
Document No. :	RM00005995-RN00_AR003
Investigator :	Faye M Johnson
Document No. :	RM00002284-RN01_AR004
Investigator :	Xiao Zhao
Document No. :	RM00007174-RN00_AR002
Investigator :	Jeffrey J Tarrand
Document No. :	RM00000118-RN02_AR002
Investigator :	Sarina Anne Piha-Paul
Document No. :	RM00005382-RN00_AR004
Investigator :	Yuan Pan
Document No. :	RM00005849-RN00_AR004
Investigator :	Vidya Gopalakrishnan
Document No. :	TA00000886-RN02_AR001
Investigator :	Kelly K Hunt
Document No. :	RM00000401-RN03_AR001
Investigator :	Andrew Dunbar
Document No. :	RM00007385-RN00_AR002
Investigator :	Vidya Gopalakrishnan
Document No. :	RM00000959-RN02_AR001
Investigator :	Robert Orłowski
Document No. :	RM00006353-RN00_AR003
Investigator :	Robert Orłowski
Document No. :	RM00002937-RN01_AR003
Investigator :	Elias Joseph Jabbour
Document No. :	RM00007172-RN00_AR002
Investigator :	Michael Spiotto
Document No. :	RM00004440-RN01_AR001
Investigator :	Guang Peng
Document No. :	RM00000645-RN02_AR001
Investigator :	Jo Ishizawa
Document No. :	RM00002261-RN01_AR004
Investigator :	Hui-Lin Pan
Document No. :	RM00000175-RN03_AR001
Investigator :	Sean M. Post
Document No. :	RM00000475-RN02_AR001
Investigator :	Jeffrey J Mollidrem
Document No. :	RM00007287-RN00_AR002

10. TERMINATIONS

20=yes; 0=no; 0-abstain; 0-recuse

Investigator :	Rick Avery Finch
Document No. :	RM00005055-RN00
Investigator :	Michael J Galko
Document No. :	TA00001742-RN01
Investigator :	Michael J Galko
Document No. :	RM00000648-RN02
Investigator :	Michael J Galko
Document No. :	TA00002968-RN01
Investigator :	Shuying Liu
Document No. :	TA00000782-RN02
Investigator :	Shuying Liu
Document No. :	RM00000152-RN02
Investigator :	Shuying Liu
Document No. :	RM00000693-RN02
Investigator :	Edwin Justin Ostrin
Document No. :	RM00005964-RN00

11. OLD BUSINESS ITEMS

There are no such business items for this meeting.

12. NEW BUSINESS ITEMS

There are no such business items for this meeting.

13. DISCUSSION ITEMS

There are no such business items for this meeting.

14. INFORMATIONAL ITEMS

Update	Description
Community Member Attendance	Manu Banadakoppa was not in attendance. Arlisa Edwards-Benford was present and counted among the votes.

15. ADJOURNMENT